September 16, 2024 08:00 AM EDTUpdated 08:19 AM
Financing
Startups

Biotech IPO mar­ket still in flux fol­low­ing flashy Fri­day triple­head­er

Kyle LaHucik

Senior Reporter

Three clin­i­cal-stage biotechs, three up­sized of­fer­ings and three first-day share spikes.

Last Fri­day’s biotech IPO triple­head­er was a mul­ti­year rar­i­ty for an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times